The immunohistochemistry of invasive and proliferative phenotype switching in melanoma: a case report.
To date there is no effective therapy for metastatic melanoma and at the molecular level the disease progression is poorly understood. A recent study by our group led to the development of a novel phenotype switching model for melanoma progression, wherein cells transition back-and-forth between states of proliferation and invasion to drive disease progression. To explore the model's clinical relevance we interrogated phenotype-specific expression patterns in human melanoma patient material. A matched primary/metastasis pair from a human melanoma patient was obtained and immunohistochemically stained for proliferative and invasive phenotype markers. These were also stained for hypoxia and blood vessel markers. Proliferative phenotype markers Melan-A and Mitf showed consistent anti-correlation with invasive phenotype marker Wnt5A and hypoxia marker Glut-1. These also correlated with observed intra-tumoural vascularization patterns. Similar pattern distributions were present in both primary and metastasis samples. Strikingly, we observed that late phase metastatic melanoma cells adopt morphologies and behaviours identical to very early phase cells. The expression patterns observed closely matched expectations derived from previous in vitro and xenografting experiments. These results highlight the likelihood that disease progression involves melanoma cells retaining the capacity to regulate the expression of metastatic potential critical factors according to changing microenvironmental conditions.
Eichhoff
Ossia M
OM
Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland.
Zipser
Marie C
MC
Xu
Mai
M
Weeraratna
Ashani T
AT
Mihic
Daniela
D
Dummer
Reinhard
R
Hoek
Keith S
KS
D000951:Antigens, Neoplasm / Q000235:genetics / Q000378:metabolism; D018450:Disease Progression; D005260:Female; D005706:Gallbladder Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D015870:Gene Expression; D020869:Gene Expression Profiling; D006801:Humans; D007150:Immunohistochemistry; D058965:MART-1 Antigen; D008545:Melanoma / Q000235:genetics / Q000378:metabolism / Q000473:pathology* / Q000556:secondary; D051739:Microphthalmia-Associated Transcription Factor / Q000235:genetics / Q000378:metabolism; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics / Q000378:metabolism; D020411:Oligonucleotide Array Sequence Analysis; D010641:Phenotype; D012878:Skin Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology*
D000951:Antigens, Neoplasm; D058965:MART-1 Antigen; C497234:MITF protein, human; C548667:MLANA protein, human; D051739:Microphthalmia-Associated Transcription Factor; D009363:Neoplasm Proteins